The major factors driving the market for Intra-Uterine Contraceptive Devices (IUCD), such as growing awareness of contraceptive, increased rate of unplanned pregnancies, rising number of initiatives undertaken by the private firms, technological advancements and favourable insurance for IUCD’s.
- Advertising -
Intra-Uterine Contraceptive Devices Market Categories: Segmentation
Global Intra-Uterine Contraceptive Devices Market, By Product Type (Hormonal IUCD, Copper IUCD), End-User (Hospitals, Gynaecology Clinics, Community Healthcare), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa)
This report consists of below pages:
- No of pages: 171
- No of Figures: 46
- No of Tables: 134
For a Free Sample Report @databridgemarketresearch.com/reque…ve-devices-market
TABLE OF CONTENTS:
- MARKET SEGMENTATION
- MARKET OVERVIEW
- EXECUTIVE SUMMARY
- PREMIUM INSIGHTS
- GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET, BY PRODUCT TYPE
- GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET, BY GEOGRAPHY
7.2. NORTH AMERICA INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET
- Advertising -
EUROPE INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET
7.4. APAC INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET
7.5. SOUTH AMERICA INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET
- GLOBAL INTRA-UTERINE CONTRACEPTIVE (IUCD) DEVICES MARKET, COMPANY SHARE
8.1. COMPANY SHARE ANALYSIS: GLOBAL
8.2. COMPANY SHARE ANALYSIS: NORTH AMERICA
8.3. COMPANY SHARE ANALYSIS: EUROPE
8.4. COMPANY SHARE ANALYSIS: ASIA PACIFIC
8.5. COMPANY SHARE ANALYSIS: SOUTH AMERICA
8.6. COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
- COMPANY PROFILES
9.1. BAYER AG
9.2. TEVA PHARMACEUTICAL INDUSTRIES LTD.
9.3. ALLERGEN PLC
9.4. DKT INTERNATIONAL
9.4.1. COMPANY OVERVIEW
9.4.2. REVENUE ANALYSIS
9.4.3. PRODUCT PORTFOLIO
9.5. SMB CORPORATION
9.5.1. COMPANY OVERVIEW
9.5.2. REVENUE ANALYSIS
9.5.3. PRODUCT PORTFOLIO
9.5.4. RECENT DEVELOPMENTS
9.5.5. DATA BRIDGE ANALYSIS
9.6. OCON MEDICAL LTD.
9.6.1. COMPANY OVERVIEW
9.6.2. REVENUE ANALYSIS
9.6.3. PRODUCT PORTFOLIO
9.6.4. RECENT DEVELOPMENTS
9.6.5. DATA BRIDGE ANALYSIS
9.7. MONA LISA N.V.
9.7.1. COMPANY OVERVIEW
9.7.2. REVENUE ANALYSIS
9.7.3. PRODUCT PORTFOLIO
9.7.4. RECENT DEVELOPMENTS
9.8. MEDISAFE DISTRIBUTION INC.
9.8.1. COMPANY OVERVIEW
9.8.2. REVENUE ANALYSIS
9.8.3. PRODUCT PORTFOLIO
9.8.4. RECENT DEVELOPMENTS
- RELATED REPORTS
Some of the major factors driving the market for Intra-Uterine Contraceptive Devices (IUCD), such as growing awareness of contraceptive, increased rate of unplanned pregnancies, rising number of initiatives undertaken by the private firms, technological advancements and favourable insurance for IUCD’s.
Increased Rate of Unplanned Pregnancies:
Adolescents most commonly use contraceptive methods with relatively high typical use failure rates such as condoms, withdrawal, or oral contraceptive (OC) pills. Non-use, inconsistent use, and use of methods with high typical use failure rates are reflected in the high rate of unintended adolescent pregnancies in the U.S.
Rising Number of Initiatives Undertaken By the Private Firms:
The increasing number of initiatives taken by the U.S. government has helped to limit the rising number of unplanned pregnancies and abortions rate in the U.S.
In addition, many U.S.-based private firms also contribute towards the solutions for pregnancy-related issues, which include maternal mortality, teenage pregnancies, growing number of abortions, and so on, by promoting the use of contraceptives, such as intrauterine contraceptive devices.
Favourable Insurance for IUCD’s:
The insurance policy is propelling the IUCD market towards growth. In Finland, national insurance covers acute but not preventive care, and contraceptives are usually paid by the patient.
In Sweden, the copper IUCDs are available free of cost, whereas hormonal IUCDs are not. All FDA-approved contraceptives in the U.S.
are covered by insurance.
Growing Awareness of Contraceptive:
The need to avoid unwanted pregnancies, especially among teenagers, is one of the major drivers for this market. It has also been observed that for over half of the users also identify non-contraceptive health benefits, such as treatment for excessive menstrual bleeding, menstrual pain and acne, as reasons for use.
This is also one of the factors contributing to the growth of the market in Europe.
Speak to Analyst about this Market Visit @ databridgemarketresearch.com/speak…ve-devices-market
Some of the major players operating in this market are:
- Bayer AG
- Teva Pharmaceuticals Industries Ltd.
- Mona Lisa N.V.
- DKT International
- Egemen International
- Melbea AG, Ocon Medical Ltd.
- Pregna International Limited
- Medical Engineering Corporation SA
- SMB Corporation and Meril Life Sciences Pvt. Ltd.
- Medu Scientific Ltd
- China RH Contraceptives Co., Ltd
- Sanghai Jolly Medical Education Co., Ltd
- Bernstein Leibhard LLP
- ZheijangDaji Medical Instruments, Ltd.
- Nimble International
- AME Line
- Com Ltd
The Global Intra-Uterine Contraceptiv…ces Market is highly concentrated to a few big players and rest to local players who cater to domestic markets only. Bayer AG dominated the IUCD devices market accounting for a highest market share in 2016, followed by Teva Pharmaceuticals Industries Ltd., and Mona Lisa N.V.
Some of the other players in this market include DKT International, Egemen International, Melbea AG, Ocon Medical Ltd., Pregna International Limited, Medical Engineering Corporation SA and, SMB Corporation and Meril Life Sciences Pvt. Ltd., Medu Scientific Ltd, China RH Contraceptives Co., Ltd, Sanghai Jolly Medical Education Co., Ltd, Bernstein Leibhard LLP, ZheijangDaji Medical Instruments, Ltd., Nimble International, AME Line, Technico, Cepeo, Contraceptivos, InjeflexInd And Com Ltda, Bersil, Amed among others holds 34.0% of the IUCDdelivery market in 2016.
BAYER HEALTHCARE AG
Founded in 1863 and headquartered in Leverkusen, Germany, Bayer AG is a provider of healthcare, nutrition, and high-technology materials and services. The company has three business segments, namely, HealthCare, Crop Science, and Material Science.
The HealthCare segment offers a wide range of products under animal health, pharmaceuticals, consumer care, and medical care. The pharmaceutical business offers a wide range of products in the therapeutic area of oncology, haematology, and ophthalmology, and offers products for women’s health and cardiology therapeutic applications
In October 2016, Bayer AG has successfully concluded the European registration procedure to gain EUwide marketing authorization for its new low-dose levonorgestrel-releasing intrauterine system (LNGIUS). The product is named Kyleena and will be available in the market from 2017 January.
In September 2016, Bayer AG has successfully received FDA approval for its new low-dose levonorgestrel releasing intrauterine system (LNG-IUS) “Kyleena” The launch of this product in October in U.S.
Read more about the Global Intra-Uterine Contraceptive Devices Market visit @ databridgemarketresearch.com/repor…e-devices-market/
Category: Market Research Publishers and RetailersCompany profile: Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data bridge is an aftermath of sheer wi ...
For more information: